SG11201810793XA - Pharmaceutical combinations - Google Patents
Pharmaceutical combinationsInfo
- Publication number
- SG11201810793XA SG11201810793XA SG11201810793XA SG11201810793XA SG11201810793XA SG 11201810793X A SG11201810793X A SG 11201810793XA SG 11201810793X A SG11201810793X A SG 11201810793XA SG 11201810793X A SG11201810793X A SG 11201810793XA SG 11201810793X A SG11201810793X A SG 11201810793XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pharmaceutical combinations
- pharmaceutically acceptable
- pct
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345389P | 2016-06-03 | 2016-06-03 | |
| PCT/US2017/035653 WO2017210538A1 (en) | 2016-06-03 | 2017-06-02 | Pharmaceutical combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810793XA true SG11201810793XA (en) | 2018-12-28 |
Family
ID=60477982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810793XA SG11201810793XA (en) | 2016-06-03 | 2017-06-02 | Pharmaceutical combinations |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10485788B2 (https=) |
| EP (1) | EP3463345B1 (https=) |
| JP (2) | JP6805336B2 (https=) |
| KR (1) | KR102439911B1 (https=) |
| CN (1) | CN109890386B (https=) |
| AU (1) | AU2017275650B2 (https=) |
| BR (1) | BR112018074941A2 (https=) |
| CA (1) | CA3026361A1 (https=) |
| CL (1) | CL2018003421A1 (https=) |
| CO (1) | CO2019000010A2 (https=) |
| CR (1) | CR20190002A (https=) |
| DK (1) | DK3463345T3 (https=) |
| FI (1) | FI3463345T3 (https=) |
| HU (1) | HUE060653T2 (https=) |
| IL (1) | IL263431A (https=) |
| MA (1) | MA45187A (https=) |
| MX (1) | MX387795B (https=) |
| PH (1) | PH12018502549A1 (https=) |
| PL (1) | PL3463345T3 (https=) |
| PT (1) | PT3463345T (https=) |
| RU (1) | RU2759669C2 (https=) |
| SG (1) | SG11201810793XA (https=) |
| SI (1) | SI3463345T1 (https=) |
| UA (1) | UA125436C2 (https=) |
| WO (1) | WO2017210538A1 (https=) |
| ZA (1) | ZA201900019B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX387795B (es) | 2016-06-03 | 2025-03-19 | Array Biopharma Inc | Combinaciones farmaceuticas. |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| ES2952265T3 (es) | 2017-05-02 | 2023-10-30 | Novartis Ag | Terapia combinada que comprende un inhibidor de Raf y trametinib |
| ES3025633T3 (en) | 2019-05-13 | 2025-06-09 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| CA3150474A1 (en) * | 2019-10-11 | 2021-04-15 | Geraint Iwan Davies | Drug dosage determination devices and methods |
| WO2021163072A1 (en) * | 2020-02-10 | 2021-08-19 | Cedars-Sinai Medical Center | Method of treating pancreatic cancer |
| JP7288220B2 (ja) | 2021-03-29 | 2023-06-07 | ダイキン工業株式会社 | モータ、送風装置、および冷凍装置 |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| CN120359214A (zh) * | 2022-12-15 | 2025-07-22 | 豪夫迈·罗氏有限公司 | 用于癌症治疗的组合疗法 |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2008120004A1 (en) | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
| SI2324008T1 (sl) | 2008-07-24 | 2012-08-31 | Nerviano Medical Sciences Srl | 3,4-diarilpirazoli kot protein-kinazni inhibitorji |
| JP5527878B2 (ja) * | 2009-07-30 | 2014-06-25 | トムソン ライセンシング | 表示装置及び音声出力装置 |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| CA2838736A1 (en) * | 2011-06-07 | 2012-12-13 | Caris Mpi, Inc. | Molecular profiling for cancer |
| CN108542906A (zh) * | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
| ES2695099T3 (es) | 2011-11-23 | 2019-01-02 | Array Biopharma Inc | Formulaciones farmacéuticas |
| AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| TR201904980T4 (tr) * | 2012-08-07 | 2019-05-21 | Novartis Ag | Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar. |
| AR099630A1 (es) * | 2012-10-19 | 2016-08-10 | Novartis Ag | Preparación de un inhibidor de mek y formulación que lo comprende |
| US20150273057A1 (en) * | 2012-10-25 | 2015-10-01 | Glaxosmithkline Llc | Combination |
| UA118846C2 (uk) | 2013-03-21 | 2019-03-25 | Новартіс Аг | Комбінована терапія |
| WO2015008729A1 (ja) * | 2013-07-18 | 2015-01-22 | 株式会社ダイセル | 酸化物の製造方法 |
| US20150087279A1 (en) * | 2013-09-20 | 2015-03-26 | Better Mousetrap, LLC | Mobile accident processing system and method |
| CN106029074A (zh) * | 2013-12-12 | 2016-10-12 | 诺华股份有限公司 | 用于治疗癌症的曲美替尼、帕尼单抗和达拉菲尼组合 |
| CN105566225A (zh) * | 2015-02-16 | 2016-05-11 | 苏州晶云药物科技有限公司 | 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法 |
| WO2016155670A1 (zh) * | 2015-04-01 | 2016-10-06 | 苏州晶云药物科技有限公司 | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 |
| WO2017019279A1 (en) | 2015-07-27 | 2017-02-02 | Southern Research Institute | Methods and compositions to treat cancers involving egfr |
| MX387795B (es) | 2016-06-03 | 2025-03-19 | Array Biopharma Inc | Combinaciones farmaceuticas. |
-
2017
- 2017-06-02 MX MX2018014973A patent/MX387795B/es unknown
- 2017-06-02 KR KR1020187037798A patent/KR102439911B1/ko active Active
- 2017-06-02 FI FIEP17807555.2T patent/FI3463345T3/fi active
- 2017-06-02 DK DK17807555.2T patent/DK3463345T3/da active
- 2017-06-02 JP JP2019515782A patent/JP6805336B2/ja active Active
- 2017-06-02 CA CA3026361A patent/CA3026361A1/en active Pending
- 2017-06-02 PT PT178075552T patent/PT3463345T/pt unknown
- 2017-06-02 MA MA045187A patent/MA45187A/fr unknown
- 2017-06-02 PL PL17807555.2T patent/PL3463345T3/pl unknown
- 2017-06-02 SI SI201731293T patent/SI3463345T1/sl unknown
- 2017-06-02 WO PCT/US2017/035653 patent/WO2017210538A1/en not_active Ceased
- 2017-06-02 HU HUE17807555A patent/HUE060653T2/hu unknown
- 2017-06-02 CR CR20190002A patent/CR20190002A/es unknown
- 2017-06-02 AU AU2017275650A patent/AU2017275650B2/en not_active Ceased
- 2017-06-02 BR BR112018074941-9A patent/BR112018074941A2/pt not_active Application Discontinuation
- 2017-06-02 UA UAA201813074A patent/UA125436C2/uk unknown
- 2017-06-02 CN CN201780048857.2A patent/CN109890386B/zh active Active
- 2017-06-02 RU RU2018146812A patent/RU2759669C2/ru active
- 2017-06-02 EP EP17807555.2A patent/EP3463345B1/en not_active Revoked
- 2017-06-02 SG SG11201810793XA patent/SG11201810793XA/en unknown
-
2018
- 2018-11-30 CL CL2018003421A patent/CL2018003421A1/es unknown
- 2018-12-03 PH PH12018502549A patent/PH12018502549A1/en unknown
- 2018-12-03 US US16/208,172 patent/US10485788B2/en active Active
- 2018-12-03 IL IL263431A patent/IL263431A/en unknown
-
2019
- 2019-01-02 ZA ZA2019/00019A patent/ZA201900019B/en unknown
- 2019-01-02 CO CONC2019/0000010A patent/CO2019000010A2/es unknown
- 2019-09-24 US US16/580,505 patent/US11376239B2/en active Active
-
2020
- 2020-12-03 JP JP2020201152A patent/JP2021054832A/ja active Pending
-
2022
- 2022-05-16 US US17/745,136 patent/US20230044943A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810793XA (en) | Pharmaceutical combinations | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201807965YA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| SG11201803728YA (en) | Topical pharmaceutical formulations for treating inflammatory-related conditions | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201907199QA (en) | Cancer treatment | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |